India offered 7.5 million doses of Moderna coronavirus vaccine: report

Moderna's COVID-19 vaccine was granted emergency use authorisation by India's drug regulator last month.

Moderna vaccine
Photo: Shutterstock
Press Trust of India New Delhi
2 min read Last Updated : Jul 20 2021 | 1:25 AM IST

India has been offered 7.5 million doses of Moderna's COVID-19 vaccine through the COVAX global vaccine sharing programme, but it is not clear when the jabs will arrive in the country as a consensus on the indemnity clause is yet to be reached, sources said.

The government last week said that it is working actively with vaccine manufacturer Moderna to see how its vaccine can be made available in the country.

Moderna's COVID-19 vaccine was granted emergency use authorisation by India's drug regulator last month.

"India has been offered 7.5 million doses of Moderna's COVID-19 vaccine through the COVAX global vaccine sharing programme," a source said.

However, there is no clarity so far when the shots would be available in India as "the talks are still on and a consensus on the indemnity issue is yet to be reached," a source said.

On the availability of Moderna vaccine in the country, NITI Aayog member (Health) Dr V K Paul had recently said the government is working actively with Moderna to see how its vaccine can be imported and made available in the country.

"...to and fro (talks) are going on over the contractual specifics. Discussions have not yet concluded. We are making efforts as to it happens at the earliest. We are now expecting to hear from them anytime. Currently, they have to respond to some of the points we have made and we will take it forward," he said on Friday.

According to sources, the Indian government has put forth certain conditions for finalising the indemnity clause contract and has sent it to the US drug manufacturer for their perusal.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jul 20 2021 | 1:18 AM IST

Next Story